ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Vanderbilt, Jonsson Centers Win NCI SPORE Grants.

May 18, 2001

New Policy on Minor Changes in Trials Requires Halt in Patient Enrollment.

April 25, 2008

Managed Care Plans Seek Cost Efficacy, Not Research, Center Directors Warned

March 17, 1995

Substance From Sea Squirts In Phase II For Breast Cancer

November 29, 2002

FDA Approves Medication For Smoking Cessation

May 26, 2006

Celecoxib Effective To Prevent Colon Adenomas, Study Finds

April 25, 2008